Engineered donor cells take on tough lymphomas and leukemias

NCT ID NCT05878184

Ongoing Disease control Sponsor: Sana Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests SC291, a CAR T-cell therapy made from donor cells, in 16 adults with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal is to check safety and see if the treatment can shrink tumors. Because it uses donor cells, it could be available faster than personalized therapies, but it also carries risks of immune reactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SC291 (a type of CAR T-cell therapy made from donor cells)
What this could lead to: If it works, this could provide a new treatment option for people with hard-to-treat blood cancers who have run out of standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 16 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma large B-cell lymphoma Lymphoma, B-Cell, Marginal Zone mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Linear Clinical Research Ltd

Nedlands, Western Australia, 6009, Australia
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Northside Hospital

Atlanta, Georgia, 30342, United States
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
Stanford Cancer Institute

Palo Alto, California, 94304, United States
University of Kansas Medical Center

Fairway, Kansas, 66205, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.